News in New FDA Drug Approvals

"Donanemab's compelling clinical trial outcome not only confirms that this treatment strategy is effective in treating Alzheimer's disease, but also provides clinicians additional opportunities to tailor the amyloid monoclonal antibody to the individual patient," said MBWC Clinical Trials Director, Michael Rosenbloom, MD

Read More

Categories: Science Updates, New FDA Drug Approvals, News

Members of the ADRC team wish you a happy and healthy new year! We would like to update you on our progress and express how much we appreciate your ongoing participation. Enjoy this video!

Read More

Categories: Science Updates, New FDA Drug Approvals, En Español

The drug has been shown to reduce cognitive decline in patients with early Alzheimer's.

Read More

Categories: Science Updates, New FDA Drug Approvals, News

Dr. Angela Hanson's lab team reports back on interesting talks about what’s coming soon in diagnosis, treatment, and prevention of Alzheimer’s and other diseases that lead to cognitive impairment and dementia.

Read More

Categories: Science Updates, New FDA Drug Approvals, Care & Treatment , News

Michael Rosenbloom, MD is a behavioral neurologist and the director of clinical trials for the UW Memory and Brain Wellness Center at the UW ADRC

Read More

Categories: New FDA Drug Approvals, Care & Treatment , Team Spotlights, News

On Thurs. September 14, 2023, the UW MBWC hosted a webinar for patients, families, and the wider community regarding the newly approved infusion medication Leqembi (lecanemab) for the treatment of Alzheimer's. You can watch the webinar recording here.

Read More

Categories: Science Updates, New FDA Drug Approvals, Care & Treatment , News

Our team would like to share some information about the FDA fully approved drug lecanemab (brandname Leqembi) with our patients and community.

Read More

Categories: Science Updates, New FDA Drug Approvals, Care & Treatment , News

Our team at the UW Memory and Brain Wellness Center was excited to learn about the FDA’s approval of aducanumab for use in certain individuals with Alzheimer’s disease, and would like to share some information about this newest therapy with our patients.

Read More

Categories: New FDA Drug Approvals, Care & Treatment , News